Seminars in Nuclear Medicine
Volume 40, Issue 2 , Pages 105-121 , March 2010

Radioembolization of Liver Tumors With Yttrium-90 Microspheres

References 

  1. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: A state-of-the-art brachytherapy treatment for primary and secondary liver malignancies (Part 1: Technical and methodologic considerations). J Vasc Interv Radiol. 2006;17:1251–1278
  2. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818–825discussion 825-827
  3. Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: Analysis of 1,803 consecutive cases over the past decade. Ann Surg. 2002;236:397–406discussion 406-397
  4. Mulcahy MF, Lewandowski RJ, Ibrahim SM, et al. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer. 2009;115:1849–1858
  5. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: A consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68:13–23
  6. Dawson LA, Normolle D, Balter JM, et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002;53:810–821
  7. Greco C, Catalano G, Di Grazia A, et al. Radiotherapy of liver malignancies (From whole liver irradiation to stereotactic hypofractionated radiotherapy). Tumori. 2004;90:73–79
  8. Murthy R, Nunez R, Szklaruk J, et al. Yttrium-90 microsphere therapy for hepatic malignancy: Devices, indications, technical considerations, and potential complications. Radiographics. 2005;25(suppl 1):S41–S55
  9. Campbell AM, Bailey IH, Burton MA. Analysis of the distribution of intra-arterial microspheres in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol. 2000;45:1023–1033
  10. Lien WM, Ackerman NB. The blood supply of experimental liver metastases (II. A microcirculatory study of the normal and tumor vessels of the liver with the use of perfused silicone rubber). Surgery. 1970;68:334–340
  11. Sirtex Medical Limited. Sirtex medical training manual, training program physicians and institutions. Australia http://www.sirtex.com/usa/_data/page/549/TRN-US-0320for20US1.pdfAccessed October 16, 2007
  12. Sarfaraz M, Kennedy AS, Lodge MA, et al. Radiation absorbed dose distribution in a patient treated with yttrium-90 microspheres for hepatocellular carcinoma. Med Phys. 2004;31:2449–2453
  13. Sarfaraz M, Kennedy AS, Cao ZJ, et al. Physical aspects of yttrium-90 microsphere therapy for nonresectable hepatic tumors. Med Phys. 2003;30:199–203
  14. Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med. 2000;41:1673–1681
  15. Stubbs RS, Cannan RJ, Mitchell AW. Selective internal radiation therapy (SIRT) with 90Yttrium microspheres for extensive colorectal liver metastases. Hepatogastroenterology. 2001;48:333–337
  16. Lawrence TS, Robertson JM, Anscher MS, et al. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 1995;31:1237–1248
  17. Salem R, Lewandowski R, Roberts C, et al. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol. 2004;15:335–345
  18. Lewandowski RJ, Thurston KG, Goin JE, et al. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: Response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol. 2005;16:1641–1651
  19. Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): Safety, tumor response, and survival. J Vasc Interv Radiol. 2005;16:1627–1639
  20. Delbeke D, Vitola JV, Sandler MP, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med. 1997;38:1196–1201
  21. Arulampalam TH, Francis DL, Visvikis D, et al. FDG-PET for the pre-operative evaluation of colorectal liver metastases. Eur J Surg Oncol. 2004;30:286–291
  22. Bohm B, Voth M, Geoghegan J, et al. Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors. J Cancer Res Clin Oncol. 2004;130:266–272
  23. Ogunbiyi OA, Flanagan FL, Dehdashti F, et al. Detection of recurrent and metastatic colorectal cancer: Comparison of positron emission tomography and computed tomography. Ann Surg Oncol. 1997;4:613–620
  24. Herbertson RA, Scarsbrook AF, Lee ST, et al. Established, emerging and future roles of PET/CT in the management of colorectal cancer. Clin Radiol. 2009;64:225–237
  25. MacManus M, Nestle U, Rosenzweig KE, et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol. 2009;91:85–94
  26. Yang M, Martin DR, Karabulut N, et al. Comparison of MR and PET imaging for the evaluation of liver metastases. J Magn Reson Imaging. 2003;17:343–349
  27. Jakobs T. Radiological detection and assessment of tumor response. In:  Bilbao JI,  Reiser MF editor. Liver Radioembolization with 90Y Microspheres. New York, NY: Springer; 2008;p. 93–106
  28. Roedl JB, Halpern EF, Colen RR, et al. Metabolic tumor width parameters as determined on PET/CT predict disease-free survival and treatment response in squamous cell carcinoma of the esophagus. Mol Imaging Biol. 2009;11:54–60
  29. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun. 2002;296:580–583
  30. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med. 1998;39:990–995
  31. Kwee SA, DeGrado TR, Talbot JN, et al. Cancer imaging with fluorine-18-labeled choline derivatives. Semin Nucl Med. 2007;37:420–428
  32. Talbot JN, Gutman F, Fartoux L, et al. PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: Preliminary comparison with [(18)F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2006;33:1285–1289
  33. Yamamoto Y, Nishiyama Y, Kameyama R, et al. Detection of hepatocellular carcinoma using 11C-choline PET: Comparison with 18F-FDG PET. J Nucl Med. 2008;49:1245–1248
  34. Covey AM, Brody LA, Maluccio MA, et al. Variant hepatic arterial anatomy revisited: Digital subtraction angiography performed in 600 patients. Radiology. 2002;224:542–547
  35. Liu DM, Salem R, Bui JT, et al. Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol. 2005;16:911–935
  36. Leung TW, Lau WY, Ho SK, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys. 1995;33:919–924
  37. Lewandowski RJ, Sato KT, Atassi B, et al. Radioembolization with 90Y microspheres: Angiographic and technical considerations. Cardiovasc Intervent Radiol. 2007;30:571–592
  38. Ahmadzadehfar H, Sabet A, Biermann K, et al. The significance of Tc-99m-MAA SPECT-CT liver perfusion imaging in treatment planning for yttrium 90 microsphere selective internal radiation treatment. [meeting abstracts 2] J Nucl Med. 2009;50:1662
  39. Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys. 1998;40:583–592
  40. TheraSphere Yttrium-90 Glass Microspheres Users Manual. MDS Nordion, Ottawa, Ontario, Canada
  41. Salem R, Hunter RD. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma: A review. Int J Radiat Oncol Biol Phys. 2006;66(suppl 2):S83–S88
  42. Hamami ME, Poeppel TD, Muller S, et al. SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer. J Nucl Med. 2009;50:688–692
  43. Kennedy AS, Coldwell D, Nutting C, et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: Modern USA experience. Int J Radiat Oncol Biol Phys. 2006;65:412–425
  44. Moroz P, Anderson JE, Van Hazel G, et al. Effect of selective internal radiation therapy and hepatic arterial chemotherapy on normal liver volume and spleen volume. J Surg Oncol. 2001;78:248–252
  45. Lewandowski RJ, Salem R. Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver. Semin Intervent Radiol. 2006;23:64–72
  46. Murthy R, Habbu A, Salem R. Trans-arterial hepatic radioembolisation of yttrium-90 microspheres. Biomed Imaging Interv J. 2006;2:e43
  47. Riaz A, Lewandowski RJ, Kulik LM, et al. Complications following radioembolization with yttrium-90 microspheres: A comprehensive literature review. J Vasc Interv Radiol. 2009;20:1121–1130
  48. Fabbri C, Sarti G, Cremonesi M, et al. Quantitative analysis of 90Y Bremsstrahlung SPECT-CT images for application to 3D patient-specific dosimetry. Cancer Biother Radiopharm. 2009;24:145–154
  49. Minarik D, Sjogreen Gleisner K, Ljungberg M. Evaluation of quantitative (90)Y SPECT based on experimental phantom studies. Phys Med Biol. 2008;53:5689–5703
  50. Murthy R, Brown DB, Salem R, et al. Gastrointestinal complications associated with hepatic arterial yttrium-90 microsphere therapy. J Vasc Interv Radiol. 2007;18:553–562
  51. Carretero C, Munoz-Navas M, Betes M, et al. Gastroduodenal injury after radioembolization of hepatic tumors. Am J Gastroenterol. 2007;102:1216–1220
  52. Salem R, Parikh P, Atassi B, et al. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol. 2008;31:431–438
  53. Leung WT, Lau WY, Ho SK, et al. Measuring lung shunting in hepatocellular carcinoma with intrahepatic-arterial technetium-99m macroaggregated albumin. J Nucl Med. 1994;35:70–73
  54. Yip D, Allen R, Ashton C, et al. Radiation-induced ulceration of the stomach secondary to hepatic embolization with radioactive yttrium microspheres in the treatment of metastatic colon cancer. J Gastroenterol Hepatol. 2004;19:347–349
  55. Vente MA, Wondergem M, van der Tweel I, et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: A structured meta-analysis. Eur Radiol. 2009;19:951–959
  56. Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: Factors associated with liver toxicities. J Vasc Interv Radiol. 2005;16(2 Pt. 1):205–213
  57. Ingold JA, Reed GB, Kaplan HS, et al. Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med. 1965;93:200–208
  58. Fox RA, Klemp PF, Egan G, et al. Dose distribution following selective internal radiation therapy. Int J Radiat Oncol Biol Phys. 1991;21:463–467
  59. Sangro B, Bilbao JI, Boan J, et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2006;66:792–800
  60. Kennedy AS, Nutting C, Jakobs T, et al. A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Invest. 2009;27:682–690
  61. Young JY, Rhee TK, Atassi B, et al. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol. 2007;18:1375–1382
  62. Toohey RE, Stabin MG, Watson EE. The AAPM/RSNA physics tutorial for residents: Internal radiation dosimetry: Principles and applications. Radiographics. 2000;20:533–546quiz 531-532
  63. Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: A risk-stratification analysis. J Vasc Interv Radiol. 2005;16(2 Pt. 1):195–203
  64. Hoffmann R, Bilbao JI, Jakobs T, et al. Complications and side effects. In:  Bilbao JI,  Reiser MF editor. Liver Radioembolization with 90Y Microspheres. New York, NY: Springer; 2008;p. 139–146
  65. Kennedy AS, McNeillie P, Dezarn WA, et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys. 2009;74:1494–1500
  66. Senzolo M, Germani G, Cholongitas E, et al. Veno occlusive disease: Update on clinical management. World J Gastroenterol. 2007;13:3918–3924
  67. Bayraktar UD, Seren S, Bayraktar Y. Hepatic venous outflow obstruction: Three similar syndromes. World J Gastroenterol. 2007;13:1912–1927
  68. Chopra R, Eaton JD, Grassi A, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: Results of the European compassionate-use study. Br J Haematol. 2000;111:1122–1129
  69. Atassi B, Bangash AK, Lewandowski RJ, et al. Biliary sequelae following radioembolization with Yttrium-90 microspheres. J Vasc Interv Radiol. 2008;19:691–697
  70. Szyszko T, Al-Nahhas A, Tait P, et al. Management and prevention of adverse effects related to treatment of liver tumours with 90Y microspheres. Nucl Med Commun. 2007;28:21–24
  71. Lewandowski RJ, Wang D, Gehl J, et al. A comparison of chemoembolization endpoints using angiographic versus transcatheter intraarterial perfusion/MR imaging monitoring. J Vasc Interv Radiol. 2007;18:1249–1257
  72. Tran LN, Brown MS, Goldin JG, et al. Comparison of treatment response classifications between unidimensional, bidimensional, and volumetric measurements of metastatic lung lesions on chest computed tomography. Acad Radiol. 2004;11:1355–1360
  73. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207–214
  74. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors (European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada). J Natl Cancer Inst. 2000;92:205–216
  75. Therasse P, Eisenhauer EA, Verweij J, et al. RECIST revisited: A review of validation studies on tumour assessment. Eur J Cancer. 2006;42:1031–1039
  76. Wahl RL, Zasadny K, Helvie M, et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation. J Clin Oncol. 1993;11:2101–2111
  77. Belton AL, Saini S, Liebermann K, et al. Tumour size measurement in an oncology clinical trial: Comparison between off-site and on-site measurements. Clin Radiol. 2003;58:311–314
  78. Marn CS, Andrews JC, Francis IR, et al. Hepatic parenchymal changes after intraarterial Y-90 therapy: CT findings. Radiology. 1993;187:125–128
  79. Tutt AN, Plunkett TA, Barrington SF, et al. The role of positron emission tomography in the management of colorectal cancer. Colorectal Dis. 2004;6:2–9
  80. Bienert M, McCook B, Carr BI, et al. Sequential FDG PET/CT in 90Y microsphere treatment of unresectable colorectal liver metastases. Eur J Nucl Med Mol Imaging. 2005;32:723
  81. Bienert M, McCook B, Carr BI, et al. 90Y microsphere treatment of unresectable liver metastases: Changes in 18F-FDG uptake and tumour size on PET/CT. Eur J Nucl Med Mol Imaging. 2005;32:778–787
  82. Selzner M, Hany TF, Wildbrett P, et al. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?. Ann Surg. 2004;240:1027–1034discussion 1035-1036
  83. Wong CY, Salem R, Raman S, et al. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: A comparison with CT or MRI. Eur J Nucl Med Mol Imaging. 2002;29:815–820
  84. Wong CY, Salem R, Qing F, et al. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: Comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med. 2004;45:1892–1897
  85. Morikawa M, Demura Y, Ishizaki T, et al. The effectiveness of 18F-FDG PET/CT combined with STIR MRI for diagnosing nodal involvement in the thorax. J Nucl Med. 2009;50:81–87
  86. Gray B, Van Hazel G, Buck M, et al. Treatment of colorectal liver metastases with SIR-Spheres plus chemotherapy. GI Cancer. 2000;3:249–257
  87. Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12:1711–1720
  88. Stubbs RS, O'Brien I, Correia MM. Selective internal radiation therapy with 90Y microspheres for colorectal liver metastases: Single-centre experience with 100 patients. ANZ J Surg. 2006;76:696–703
  89. Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol. 2004;88:78–85
  90. Sato KT, Lewandowski RJ, Mulcahy MF, et al. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres—Safety, efficacy, and survival. Radiology. 2008;247:507–515
  91. Cosimelli M, Mancini R, Carpanese L, et al: Clinical safety and efficacy of 90yttrium resin microspheres alone in unresectable, heavily pre-treated colorectal liver metastases: Results of a phase II trial. In: Proceedings from the ASCO Annual Meeting; 2008; Chicago, IL
  92. Mancini R, Carpanese L, Sciuto R, et al. A multicentric phase II clinical trial on intra-arterial hepatic radiotherapy with 90yttrium SIR-spheres in unresectable, colorectal liver metastases refractory to i.v. chemotherapy: Preliminary results on toxicity and response rates. In Vivo. 2006;20(6A):711–714
  93. Sharma RA, Van Hazel GA, Morgan B, et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol. 2007;25:1099–1106
  94. Van Hazel G, Pavlakis N, Goldstein D: Selective internal radiation therapy (SIRT) plus systemic chemotherapy with irinotecan. A phase I dose escalation study. In: Proceedings from the ASCO Annual Meeting. ASCO GI Symposium, Hollywood, FL; 2005 (abstract 265)
  95. Stubbs RS. Portal hypertension and liver surgery following selective internal radiation therapy with 90Yttrium microspheres. J Clin Oncol. 2006;24:e15
  96. Riaz A, Lewandowski RJ, Kulik L, et al. Yttrium-90 radioembolization using TheraSphere in the management of primary and secondary liver tumors. Q J Nucl Med Mol Imaging. 2009;53:311–316
  97. Geschwind JF, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology. 2004;127(5 suppl 1):S194–S205
  98. Salem R, Lewandowski RJ, Mulcahy MF, et al: Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: A comprehensive report of long-term outcomes. Gastroenterology (in press)
  99. Kulik LM, Atassi B, van Holsbeeck L, et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: Downstaging to resection, RFA and bridge to transplantation. J Surg Oncol. 2006;94:572–586
  100. Benevento A, Boni L, Frediani L, et al. Result of liver resection as treatment for metastases from noncolorectal cancer. J Surg Oncol. 2000;74:24–29
  101. Rhee TK, Lewandowski RJ, Liu DM, et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: Preliminary results from a multi-institutional experience. Ann Surg. 2008;247:1029–1035
  102. Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin Y-90-microspheres: Early results in 148 patients. Am J Clin Oncol Cancer Clin Trials. 2008;31:271–279
  103. King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer. 2008;113:921–929
  104. Kalinowski M, Dressler M, Konig A, et al. Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: A prospective single center study. Digestion. 2009;79:137–142
  105. Jakobs TF, Hoffmann RT, Fischer T, et al. Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol. 2008;19:683–690
  106. Coldwell DM, Kennedy AS, Nutting CW. Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. Int J Radiat Oncol Biol Phys. 2007;69:800–804
  107. Ibrahim SM, Mulcahy MF, Lewandowski RJ, et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: Results from a pilot study. Cancer. 2008;113:2119–2128
  108. Viadana E, Bross ID, Pickren JW. An autopsy study of some routes of dissemination of cancer of the breast. Br J Cancer. 1973;27:336–340

PII: S0001-2998(09)00105-6

doi: 10.1053/j.semnuclmed.2009.11.001

Seminars in Nuclear Medicine
Volume 40, Issue 2 , Pages 105-121 , March 2010

Article Tools

* Image Usage & Resolution